S E Pinder

Summary

Affiliation: King's College London
Country: UK

Publications

  1. doi request reprint Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation
    Sarah E Pinder
    Breast Research Pathology, Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, London, UK
    Mod Pathol 23:S8-13. 2010
  2. pmc A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial
    S E Pinder
    King s College London, Division of Cancer Studies, Research Oncology, 3rd Floor, Bermondsey Wing, Guy s Hospital, Great Maze Pond, London SE1 9RT, UK
    Br J Cancer 103:94-100. 2010
  3. doi request reprint The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example
    Sarah E Pinder
    Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, Great Maze Pond, London, UK
    J Clin Pathol 66:169-77. 2013
  4. doi request reprint Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer
    S Irshad
    Breakthrough Breast Cancer Research Unit, Department of Research Oncology, Guy s Hospital, King s College London School of Medicine, London, SE1 9RT, UK
    Breast Cancer Res Treat 144:331-41. 2014
  5. pmc Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
    R R Millis
    Hedley Atkins Cancer Research UK Breast Pathology Laboratory, Guy s Hospital, London SE1 9RT, UK
    Br J Cancer 90:1538-42. 2004
  6. ncbi request reprint Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden NHS Trust, London, UK
    J Pathol 199:418-23. 2003

Collaborators

Detail Information

Publications6

  1. doi request reprint Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation
    Sarah E Pinder
    Breast Research Pathology, Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, London, UK
    Mod Pathol 23:S8-13. 2010
    ..No biomarkers have been convincingly shown, and validated, to predict the behavior of DCIS till date...
  2. pmc A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial
    S E Pinder
    King s College London, Division of Cancer Studies, Research Oncology, 3rd Floor, Bermondsey Wing, Guy s Hospital, Great Maze Pond, London SE1 9RT, UK
    Br J Cancer 103:94-100. 2010
    ..Cases in the UKCCCR/ANZ DCIS trial have been histologically reviewed to determine the features of prognostic importance...
  3. doi request reprint The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example
    Sarah E Pinder
    Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, Great Maze Pond, London, UK
    J Clin Pathol 66:169-77. 2013
    ..We make some suggestions regarding these challenges, and propose a checklist of features that should be considered in order to stimulate debate and improve the quality of data produced by TMA analysis...
  4. doi request reprint Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer
    S Irshad
    Breakthrough Breast Cancer Research Unit, Department of Research Oncology, Guy s Hospital, King s College London School of Medicine, London, SE1 9RT, UK
    Breast Cancer Res Treat 144:331-41. 2014
    ....
  5. pmc Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
    R R Millis
    Hedley Atkins Cancer Research UK Breast Pathology Laboratory, Guy s Hospital, London SE1 9RT, UK
    Br J Cancer 90:1538-42. 2004
    ..This is in agreement with immunohistochemical and molecular data indicating that low-grade and high-grade mammary carcinomas are quite different lesions...
  6. ncbi request reprint Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden NHS Trust, London, UK
    J Pathol 199:418-23. 2003
    ..These data support an algorithm in which FISH testing is restricted to IHC 2+ tumours in reference centres. The results may not extrapolate to laboratories with less experience or using different methodologies...